Corbus Pharmaceuticals presents CRB-701 clinical responses at ESMO25

Corbus Pharmaceuticals (CRBP) announced data from its Phase 1/2 clinical study of CRB-701 will be presented as a poster at the 2025 European Society for Medical Oncology, ESMO25, Congress being held in Berlin, Germany. The poster titled, “Phase 1/2 study of the next-generation Nectin-4-targeting antibody-drug conjugate CRB-701 in patients with urothelial and non-urothelial solid tumors” by Perez et al will be presented tomorrow, October 19, 2025, from 12:00-12:45 CEST. Data as of September 1, 2025 will be presented from 167 patients, of whom 1221 were evaluable for efficacy. The tumor types being investigated were head and neck squamous cell carcinoma, cervical cancer and locally advanced/metastatic urothelial tumors. In addition, 21 patients who had other solid-tumor types were enrolled during dose escalation.